| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/16/2002 | EP1171156A1 Novel use within transplantation surgery |
| 01/16/2002 | EP1171155A2 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/16/2002 | EP1171154A2 Uses of mammalian ox2 protein and related reagents |
| 01/16/2002 | EP1171151A1 Thrombospondin-2 and uses thereof |
| 01/16/2002 | EP1171147A1 Modulation of excitable tissue function by peripherally administered erythropoietin |
| 01/16/2002 | EP1171137A1 Methods of treatment of mitochondrial disorders |
| 01/16/2002 | EP1171131A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171129A1 Use of glucosylceramide synthesis inhibitors in therapy |
| 01/16/2002 | EP1171128A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 01/16/2002 | EP1171125A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171124A2 Anthelmintic compositions |
| 01/16/2002 | EP1171121A2 Pharmaceutical compositions comprising dipeptidylpeptidase iv inhibitors for the promotion of growth |
| 01/16/2002 | EP1171120A1 Methods for alleviating discomfort of a hot flash and compositions therefor |
| 01/16/2002 | EP1171109A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 01/16/2002 | EP1171104A2 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 01/16/2002 | EP1171098A1 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
| 01/16/2002 | EP1171089A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171078A2 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 01/16/2002 | EP1170993A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 |
| 01/16/2002 | EP0914097B1 Composition and dosage form comprising opioid antagonist |
| 01/16/2002 | EP0866701B1 Synergistic immunosuppressant composition containing a 2,2'-bi-1h-pyrrole compound |
| 01/16/2002 | CN1331801A Kidney disease detection and treatment |
| 01/16/2002 | CN1331691A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331602A Methods of downmodulating immune response to therapeutic proteins |
| 01/16/2002 | CN1331591A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331590A Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating disease associated with increase of AT-1 or AT-2 receptors |
| 01/16/2002 | CN1331588A Use of 5HT2A and 5HT 2A-2C receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 01/16/2002 | CN1331587A Spray-type consmetic compsn. and matrix used in said compsn. for dermal administration |
| 01/16/2002 | CN1331576A Methods and transdermal compsns. for pain relief |
| 01/16/2002 | CN1331250A Glucoprotein having inhibitory activity to pyroric spirillar colonization |
| 01/16/2002 | CN1330921A Method of mfg. slowly-released microball by combined milk process |
| 01/15/2002 | US6339151 Forming compounds using a nucleic acid base with a phosphorous halide to form drugs for nonproliferation of cells |
| 01/15/2002 | US6339106 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 01/15/2002 | US6339088 Composition for treatment of external secretion disorders except hypol acrimation |
| 01/15/2002 | US6339085 For therapy of hypertrophy, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, heart failure subsequent to myocardial infarction, myocardial infarction, ischemia reperfusion injury, blood coagulation |
| 01/15/2002 | US6339077 Substituted 4-benzylaminoquinolines and their hetero analogs, process for their preparation, pharmaceuticals containing these compounds and use thereof |
| 01/15/2002 | US6339072 Compositions and methods for preventing restenosis following revascularization procedures |
| 01/15/2002 | US6339069 Administering formulation comprising pharmaceutically acceptable carrier; and, liposome comprising a bioactive agent and a lipid component, the lipid component comprising a peptide-lipid conjugate |
| 01/15/2002 | US6338963 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 01/15/2002 | US6338942 Selective expansion of target cell populations |
| 01/15/2002 | US6338862 Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
| 01/15/2002 | CA2160132C Use of steroid antagonists for the therapy and prophylaxis of demential illnesses |
| 01/14/2002 | CA2352496A1 Oral solid pharmaceutical formulations with ph-dependent multiphasic release |
| 01/13/2002 | CA2353057A1 Topical treatment of skin |
| 01/10/2002 | WO2002003684A2 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| 01/10/2002 | WO2002003073A1 Differential diagnosis of neurological diseases |
| 01/10/2002 | WO2002002812A2 Method for determining the susceptibility to stoke by analysing the ins gene |
| 01/10/2002 | WO2002002797A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 01/10/2002 | WO2002002780A2 Human serine-threonine kinase |
| 01/10/2002 | WO2002002772A2 Human extracellular matrix (ecm)-related tumor marker |
| 01/10/2002 | WO2002002757A2 Adenylyl and guanylyl cyclases |
| 01/10/2002 | WO2002002751A2 Alteration of cell membrane |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002641A1 Antibodies that immunospecifically bind to blys |
| 01/10/2002 | WO2002002638A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/10/2002 | WO2002002635A2 Isolated human ion channel proteins, nucleic acid molecules encoding them, and uses thereof |
| 01/10/2002 | WO2002002634A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/10/2002 | WO2002002633A2 Transporters and ion channels |
| 01/10/2002 | WO2002002629A2 Grf2-binding proteins and applications thereof |
| 01/10/2002 | WO2002002625A2 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | WO2002002624A2 B7-like molecules and uses thereof |
| 01/10/2002 | WO2002002610A2 Secretion and trafficking molecules |
| 01/10/2002 | WO2002002609A1 Inhibitory pas domain protein (ipas) and screening methods related to angiogenesis and tumor progression |
| 01/10/2002 | WO2002002607A2 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | WO2002002603A2 Protein modification and maintenance molecules |
| 01/10/2002 | WO2002002595A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | WO2002002593A2 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| 01/10/2002 | WO2002002513A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| 01/10/2002 | WO2002002509A1 Compounds and compositions for delivering active agents |
| 01/10/2002 | WO2002002147A2 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | WO2002002144A1 Medicinal preparations for treating sex hormone-dependent diseases |
| 01/10/2002 | WO2002002143A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 01/10/2002 | WO2002002134A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 01/10/2002 | WO2002002131A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/10/2002 | WO2002002128A2 Oral compositions comprising antimicrobial agents |
| 01/10/2002 | WO2002002118A1 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| 01/10/2002 | WO2002002111A1 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 01/10/2002 | WO2002002103A2 Compositions based on aminoacids, suitable for the treatment of heart failure |
| 01/10/2002 | WO2002002096A2 Oral compositions comprising host-response modulating agent |
| 01/10/2002 | WO2002002094A2 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy |
| 01/10/2002 | WO2002002093A2 Combination containing an antifolate and methylmalonic acid lowering agent |
| 01/10/2002 | WO2002002091A2 Methods and compositions for the treatment of alcoholism and alcohol dependence |
| 01/10/2002 | WO2002002085A2 Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities |
| 01/10/2002 | WO2002002079A1 Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| 01/10/2002 | WO2002002078A2 Improved liposomal camptothecins and uses thereof |
| 01/10/2002 | WO2002002077A2 Liposomal antineoplastic drugs and uses thereof |
| 01/10/2002 | WO2002002055A2 Antifungal compounds and methods of use |
| 01/10/2002 | WO2002002011A1 Dna encoding human serine protease d-g |
| 01/10/2002 | WO2002001950A2 Transgenic mice containing targeted gene disruptions |
| 01/10/2002 | WO2001094636A8 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 01/10/2002 | WO2001074164A9 Methods of modulating hair growth |
| 01/10/2002 | WO2001070775A3 Wnt-1 related polypeptides, and nucleic acids encoding the same |
| 01/10/2002 | WO2001051042A3 Treatment of diabetic ulcers |
| 01/10/2002 | WO2001050881A3 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 01/10/2002 | WO2001049250A3 Treatment of acne using lipoic acid |
| 01/10/2002 | WO2001048483A3 Method for screening of appetite control agents |
| 01/10/2002 | WO2001045730A3 Tweak receptor |
| 01/10/2002 | WO2001043691A3 Fragments and antagonists of heat shock protein 60 |
| 01/10/2002 | WO2001040279A3 Hbv sequences |